OKEP Oct'15

1.

Name:

2.

Territory:

3.

Email Id:

4.

SE has an incidence of up to 61 per 100,000 per year and an estimated mortality of __?

(A) 19 %

(B) 20%

(C) 21%

(D) 25%

5.

Clinically Stage II of the tonic-clonic convulsive SE last for ___?

(A) 5 to 10 min

(B) 10 to 20 min

(C) 10 to 30 min

(D) 30 to 60 min

6.

All AEDs commonly used as first-line treatment in SE are __?

(A) SSRI’S

(B) SNRI

(C) Benzodiazepines

(D) Opioid Antagonist

7.

Levetiracetam a low potential for interactions due to __?

(A) Maximal hepatic metabolism and low plasma protein binding.

(B) Minimal hepatic metabolism and high plasma protein binding.

(C) Maximal hepatic metabolism and high plasma protein binding

(D) Minimal hepatic metabolism and low plasma protein binding.

8.

In refractory and super-refractory SE, __ anesthetic drugs are commonly used.

(A) IV

(B) IM

(C) IN

(D) SC

9.

When treatment with an IV anesthetic for more than ___ is not successful in controlling SE, the condition can be termed super-refractory SE or malignant SE.

(A) 8

(B) 12

(C) 18

(D) 24

10.

The most commonly used bolus dose for Lacosamide was __ mg?

(A) 200 mg

(B) 300 mg

(C) 400 mg

(D) 500 mg

11.

There is general agreement that treatment of status should follow a ____ treatment protocol, so that patients may receive prompt and appropriate treatment.

(A) Staged

(B) Mixed

(C) Random

(D) Combined

12.

The relative effectiveness of levetiracetam was__, compared with phenobarbital 73.6 % phenytoin 50.2 %, and valproate 75.7 %.

(A) 68.3 %

(B) 68.4 %

(C) 68.5 %

(D) 68.6 %